Literature DB >> 28791485

Effectiveness and cost-effectiveness of an integrated care program for schizophrenia: an analysis of routine data.

Linda Kerkemeyer1, Jürgen Wasem2, Anja Neumann2, Werner Brannath3, Benjamin Mester3, Jürgen Timm3, Thomas Wobrock4,5, Claudia Bartels5, Peter Falkai6, Janine Biermann2.   

Abstract

In Germany, a regional social health insurance fund provides an integrated care program for patients with schizophrenia (IVS). Based on routine data of the social health insurance, this evaluation examined the effectiveness and cost-effectiveness of the IVS compared to the standard care (control group, CG). The primary outcome was the reduction of psychiatric inpatient treatment (days in hospital), and secondary outcomes were schizophrenia-related inpatient treatment, readmission rates, and costs. To reduce selection bias, a propensity score matching was performed. The matched sample included 752 patients. Mean number of psychiatric and schizophrenia-related hospital days of patients receiving IVS (2.3 ± 6.5, 1.7 ± 5.0) per quarter was reduced, but did not differ statistically significantly from CG (2.7 ± 7.6, 1.9 ± 6.2; p = 0.772, p = 0.352). Statistically significant between-group differences were found in costs per quarter per person caused by outpatient treatment by office-based psychiatrists (IVS: €74.18 ± 42.30, CG: €53.20 ± 47.96; p < 0.001), by psychiatric institutional outpatient departments (IVS: €4.83 ± 29.57, CG: €27.35 ± 76.48; p < 0.001), by medication (IVS: €471.75 ± 493.09, CG: €429.45 ± 532.73; p = 0.015), and by psychiatric outpatient nursing (IVS: €3.52 ± 23.83, CG: €12.67 ± 57.86, p = 0.045). Mean total psychiatric costs per quarter per person in IVS (€1117.49 ± 1662.73) were not significantly lower than in CG (€1180.09 ± 1948.24; p = 0.150). No statistically significant differences in total schizophrenia-related costs per quarter per person were detected between IVS (€979.46 ± 1358.79) and CG (€989.45 ± 1611.47; p = 0.084). The cost-effectiveness analysis showed cost savings of €148.59 per reduced psychiatric and €305.40 per reduced schizophrenia-related hospital day. However, limitations, especially non-inclusion of costs related to management of the IVS and additional home treatment within the IVS, restrict the interpretation of the results. Therefore, the long-term impact of this IVS deserves further evaluation.

Entities:  

Keywords:  Germany; Health economics evaluation; Outpatient integrated care; Routine data analysis; Statutory health insurance

Mesh:

Year:  2017        PMID: 28791485     DOI: 10.1007/s00406-017-0830-x

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  23 in total

1.  Outcome of case management based on the strengths model compared to standard care. A randomised controlled trial.

Authors:  Tommy Björkman; Lars Hansson; Mikael Sandlund
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-04       Impact factor: 4.328

2.  Does assertive community outreach improve social support? Results from the Lambeth Study of early-episode psychosis.

Authors:  Raymond Tempier; Lloyd Balbuena; Philippa Garety; Tom J Craig
Journal:  Psychiatr Serv       Date:  2012-03       Impact factor: 3.084

3.  Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

Authors:  Martin Lambert; Thomas Bock; Daniel Schöttle; Dietmar Golks; Klara Meister; Liz Rietschel; Alexandra Bussopulos; Marietta Frieling; Michael Schödlbauer; Marc Burlon; Christian G Huber; Gunda Ohm; Manoshi Pakrasi; Michael Sadre Chirazi-Stark; Dieter Naber; Benno G Schimmelmann
Journal:  J Clin Psychiatry       Date:  2010-03-23       Impact factor: 4.384

Review 4.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

5.  Clinical outcome of assertive community treatment (ACT) in a rural area in Denmark: a case-control study with a 2-year follow-up.

Authors:  Jørgen Aagaard; Klaus Müller-Nielsen
Journal:  Nord J Psychiatry       Date:  2010-12-21       Impact factor: 2.202

6.  Assessing the effectiveness of recovery-oriented ACT in reducing state psychiatric hospital use.

Authors:  Joseph P Morrissey; Marisa E Domino; Gary S Cuddeback
Journal:  Psychiatr Serv       Date:  2013-04-01       Impact factor: 3.084

7.  Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany.

Authors:  Christian Schmidt-Kraepelin; Birgit Janssen; Wolfgang Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

Review 8.  Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression.

Authors:  Tom Burns; Jocelyn Catty; Michael Dash; Chris Roberts; Austin Lockwood; Max Marshall
Journal:  BMJ       Date:  2007-07-13

9.  Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program.

Authors:  Robert Rosenheck; Douglas Leslie; Kyaw Sint; Haiqun Lin; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Joanne Severe; Agnes Rupp; Michael Schoenbaum; John M Kane
Journal:  Schizophr Bull       Date:  2016-01-31       Impact factor: 9.306

10.  Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial.

Authors:  Víðir Sigrúnarson; Rolf W Gråwe; Gunnar Morken
Journal:  BMC Psychiatry       Date:  2013-07-30       Impact factor: 3.630

View more
  1 in total

1.  Shared Reflection to Maximize Resources and Minimize Costs: The Reflecting Team Applied to a Hospital Environment.

Authors:  M M Balcells-Oliveró; L Nuño; N Freixa; I Domínguez; I Pons; E Alcover; T Gual
Journal:  Community Ment Health J       Date:  2020-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.